Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant
NCT05839119 · Brown University · PHASE1 · terminated · last registry update 2026-04-02 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Principal Investigator left institution” | – | Registry record, Brown University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GNRHR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-10Phase 3 first posted: Istituto Oncologico Veneto IRCCS, Relugolix-Neoadjuvant treatment + Relugolix-Adjuvant treatment (NCT07927777)
- 2026-11-09Results posted on the registry: Alliance Foundation Trials, LLC., Apalutamide + LHRH Analogue (NCT03009981)
- 2026-11-03Results posted on the registry: National Cancer Institute (NCI), Darolutamide + Exemestane (NCT06169124)
- 2026-10-28Also stopped (terminated): Institut National de la Santé Et de la Recherche Médicale, France, leuprorelin + Cyproterone acetate (NCT00601276)
- 2026-10-16Results posted on the registry: Yale University, Elagolix (NCT03746535)
- 2026-10-15Phase 3 first posted: Hinova Pharmaceuticals Inc., Deutenzalutamide Soft Capsules + ADT + Placebo + ADT (NCT07875881)
- 2026-10-15Also stopped (terminated): Spanish Breast Cancer Research Group, Trastuzumab + Alpelisib (NCT05063786)
- 2026-10-15Results posted on the registry: Praful Ravi, MB BCHir, MRCP, Darolutamide + Abemaciclib (NCT05617885)
- 2026-10-15Also stopped (terminated): Praful Ravi, MB BCHir, MRCP, Darolutamide + Abemaciclib (NCT05617885)
- 2026-10-14Also stopped (terminated): UNICANCER, Alpelisib + Ribociclib (NCT05625087)
- 2026-10-01Also stopped (withdrawn): British Columbia Cancer Agency, Degarelix (NCT01630967)
- 2026-09-28Also stopped (terminated): Merck Sharp & Dohme LLC, Pembrolizumab + Enzalutamide (NCT04191096)
- 2026-09-24Results posted on the registry: University of Wisconsin, Madison, Indomethacin + Placebo (NCT06253702)
- 2026-09-15Results posted on the registry: Bayer, Darolutamide (BAY1841788, Nubeqa) (NCT05059236)
- 2026-09-11Phase 3 first posted: Fundación para la Investigación del Hospital Clínico de Valencia, Human chorionic gonadotropin (hCG) + Follitropin delta (NCT07816562)
- 2026-09-02Results posted on the registry: University of Colorado, Denver, Gonadotropin Releasing Hormone Agonists (GNRH) + Androgen receptor (AR) inhibitor (NCT05700903)
- 2026-09-02Also stopped (terminated): University of Colorado, Denver, Gonadotropin Releasing Hormone Agonists (GNRH) + Androgen receptor (AR) inhibitor (NCT05700903)
- 2026-08-31Results posted on the registry: Alliance for Clinical Trials in Oncology, a drug against GNRHR (NCT05241860)
- 2026-08-26Results posted on the registry: Stephanie B. Seminara, MD, kisspeptin 112-121 + GnRH (NCT04648969)
- 2026-08-20Phase 3 first posted: Dr. Tamim Niazi, ZOLADEX 10.8 mg (NCT07777263)
- 2026-08-07Phase 3 first posted: University College, London, Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy (NCT07751133)
- 2026-07-29Results posted on the registry: Memorial Sloan Kettering Cancer Center, degarelix injection + degarelix injection (NCT01542021)
- 2026-07-08Results posted on the registry: Novartis Pharmaceuticals, Ribociclib Placebo + Ribociclib (NCT03671330)
- 2026-07-02Results posted on the registry: Dana-Farber Cancer Institute, Abemaciclib + Tamoxifen (NCT06001762)
- 2026-07-02Results posted on the registry: Washington University School of Medicine, Androgen deprivation therapy (NCT05628363)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision